Meitheal Pharmaceuticals, Inc.

Premier Breakthroughs 2024 National Harbor, MD July 23-24 The Meitheal team is on hand at this week’s Premier Breakthroughs Conference. Stop by booth #1212 to hear about the exciting things going on recently at Meitheal.    Meitheal continues to bring stabilization to Generics, expand into Biologics and Biosimilars and simplify access to life-changing medicine, for the common good.   Think sustainability, think Meitheal. #Generics #Biologics #Biosimilars

BREAKING NEWS: Meitheal Pharmaceuticals, a Chicago-based biopharmaceutical company, has acquired the U.S. rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics and Zavante Therapeutics. CONTEPO™ is a novel intravenous antibiotic product with effect against many multi-drug resistant strains of complicated urinary tract infections. “The strategic addition of CONTEPO™ to our robust product portfolio provides us with a novel therapeutic with the potential to address a significant unmet need around increasing antibiotic resistance,” stated Tom Shea, CEO of Meitheal. “As a fully integrated biopharmaceutical company, Meitheal is uniquely positioned to advance CONTEPO™ through the final stages of the regulatory process and, if approved, deliver a consistent supply of this high-quality antibiotic to patients and providers in need of an innovative option for drug resistant urinary tract infections.” Learn more about what is on the horizon at Meitheal in today’s news release: https://lnkd.in/g2ndNq9K

Meitheal Pharmaceuticals is proud to announce the launch of Vancomycin Hydrochloride for Injection, USP, 500 mg/vial and 1 g/vial, which are now available in convenient single-dose vials. Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci and belongs to the class of glycopeptide antibiotics. This launch marks the completion of Meitheal’s Vancomycin Hydrochloride product lineup in the U.S. market, and reflects Meitheal's ongoing commitment to advancing patient care and enhancing the healthcare landscape nationwide. Learn more about Vancomycin here: https://lnkd.in/dWNmF3-x

BREAKING NEWS: Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated Biopharmaceutical Company Based in Chicago, Gains Exclusive U.S. Rights to YUSIMRY®, a Biosimilar of Humira®.      YUSIMRY® (adalimumab-aqvh) is FDA-approved for nine indications as a biosimilar of Humira® (adalimumab), available in both pre-filled syringe and autoinjector presentations. Demand for adalimumab products remains high. Meitheal will continue the development of both pediatric presentations and a high concentration (100mg/mL) formulation of YUSIMRY®. “Adalimumab is a critical medication for many Americans living with autoimmune conditions, and we look forward to continuing to deliver YUSIMRY®, a more affordable option to Humira®, to patients at a fair and sustainable price,” said Brian McCarthy, Meitheal Senior V.P. of Specialty. “With adalimumab biosimilars recently gaining traction, YUSIMRY® is positioned to meet the ongoing demand for accessible, treatment options due to key macro forces and the strategic investments being made in its production and commercialization.” This new, exclusive licensing agreement for YUSIMRY® adds a fifth biosimilar and the first on-market biosimilar to Meitheal’s portfolio. Meitheal’s parent company and related entities have invested over $300 million in capital and R&D in recent years to support sustainable product supply, including investing $30 million in a monoclonal antibody drug substance facility. Learn more about what is on the horizon at Meitheal in today’s news release: https://lnkd.in/gupda_6U Think sustainability, think Meitheal. * Humira® is a registered trademark of AbbVie Inc. * YUSIMRY® is a registered trademark of Hong Kong King-Friend Industry Co., Ltd. (assignment pending) and licensed to Meitheal Pharmaceuticals, Inc.